FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Machinaton | D C | 20540 | |
|-------------|------|-------|--|
| Washington, | D.C. | 20549 | |

| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP |
|--|
|--|

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Last) C/O CEF | nd Address of John (F REVEL THE | | Susuer Name and Ticker or Trading Symbol Cerevel Therapeutics Holdings, Inc. [CERE] Date of Earliest Transaction (Month/Day/Year) 02/09/2022 | | | | | | | | elationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner Officer (give title below) Chief Scientific Officer | | | | | | | |
|---|--|------------------------------------|---|-----------------------------------|--|----------------------------------|---|------------------|---------------------------|--------------------|---|-------------------------------------|---|--|-----------------------|--|------------------------------------|--|
| (Street) CAMBR (City) | | 1A State) | 02421 (Zip) | | 4. If Amendment, Date of Original Filed (Month/Day/Year) ative Securities Acquired, Disposed of, or Benefic | | | | | | | Line) | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| 1. Title of Security (Instr. 3) 2. Trans: Date | | | 2. Transac | action 2A. Deemed Execution Date, | | 3. Transaction Code (Instr. 2.1) | | I (A) or | or 5. Amount of | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | |
| | | | | | | | Code | v | Amount (A) o | | Price | Transaction(s) (Instr. 3 and 4) | | | | | | |
| Common Stock 02/09 | | | | | /2022 | | M ⁽¹⁾ | | 25,000 | A | \$3.5 | 26,980 | | D | | | | |
| Common Stock 02/09 | | | | |)/2022 | | S ⁽¹⁾ | | 25,000 | D | \$30 | 1,980 | | | D | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | Date Exe (Month/Day/Year) if an | 3A. Deemed Execution Date, if any (Month/Day/Year) | Code | Transaction Code (Instr. | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | Exerci on Da Day/Ye | | 7. Title an of Securit Underlyin Derivative (Instr. 3 an | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported | re es ally g | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership ct (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisa | able | Expiration Date | Title | Amount or Number of Shares | | Transactio (Instr. 4) | | | | |
| Stock Option (Right to Buy) | \$3.5 | 02/09/2022 | | M ⁽¹⁾ | | | 25,000 | (2) | | 04/02/2029 | Common Stock 25 | | \$0.00 | 345,875 | | D | | |
| Stock Option (Right to Buy) | \$30.36 | 02/09/2022 | | A | | 168,856 | | (3) | | 02/09/2032 | Common Stock | 168,856 | \$0.00 | 168,8 | 356 | D | | |

Explanation of Responses:

- 1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
- 2. 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
- $3.\ 25\% \ of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.$

Remarks:

/s/ Mark Bodenrader, as Attorney-in-Fact

02/11/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.